Larry Green, Ph.D., Chief Executive Officer
Dr. Green is a globally-recognized expert in the development and use of transgenic mice for the discovery of human therapeutic antibodies. He is an inventor of more than 60 issued and pending U.S. patents on antibody discovery technologies, antibody development technologies and therapeutic product candidates. He joined Aliva Biopharmaceuticals as chief executive officer in September 2008, closing a $12 million Series A financing round in December 2009, concomitant with the formation of Ablexis and at which time Aliva Biopharmaceuticals Inc. became a subsidiary of Ablexis.
He began his professional career at Cell Genesys in 1992 and was a scientific founder of its spin-out, Abgenix, serving in an executive leadership role at the time of Abgenix's $2.2 billion acquisition by Amgen in 2006. He is a co-inventor of Abgenix's (now Amgen's) XenoMouse® technology and led the successful design and creation of multiple enhancements to that technology platform. During his tenure at Abgenix, Dr. Green led or significantly contributed to at least 60 therapeutic antibody discovery projects that resulted in lead candidates in clinical trials, pre-clinical development or research for the pipelines of Abgenix or its partners. He has consulted for biotechnology companies, legal firms and venture capitalists in areas of antibody and biologic drug discovery and development, platform technology creation and use for biologic drug discovery and enhancement, target identification and validation, product and technology in-licensing, and matters of intellectual property.
Dr. Green received his Ph.D. from the University of Wisconsin-Madison and conducted post-doctoral work at the University of Colorado-Boulder and Stanford University. He has a B.S. with honors in chemistry from the University of Kentucky. He was elected to Phi Beta Kappa and Sigma Xi.
Jake Bauer, Vice President, Business Operations and Head of Corporate Development
As vice president, business operations and head of corporate development, Mr. Bauer leads development and implementation of the company’s corporate strategy and business development activities, and oversees Ablexis’ business operations. Mr. Bauer has more than a decade of experience in corporate development, business development, entrepreneurship and business operations. He was previously a principal at Third Rock Ventures, where he identified, evaluated and developed new opportunities for investment, negotiated financings and assisted with start-up, corporate development and operations of portfolio companies. He was also actively involved in a variety of leading biopharmaceutical companies including Ablexis, Agios, CytomX and Zafgen. Prior to joining Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals and was previously a management consultant at Putnam Associates. He received an M.B.A. from Harvard Business School, and a B.Sc. in Biology and B.A. in Economics from Duke University.
Hiroaki Shizuya, M.D., Ph.D., Resident Advisor, Molecular Biology
Dr. Shizuya is the creator of bacterial artificial chromosome (BAC) technology. He is an author on more than 50 research publications on bacterial genetics, DNA vector creation, genomic library construction and genome characterization, including that of the initial sequencing and characterization of the human genome. Dr. Shizuya’s contributions to the field are reflected in his experience as an inventor of several patents on methods and tools for genetic engineering.
Dr. Shizuya founded Aliva Biopharmaceuticals in 2001 to capitalize on the unique capabilities of BACs to stably capture and maintain up to several hundreds of kilobases of genomic DNA and to use them for purposes of modifying mammalian genomes. Prior to founding Aliva Biopharmaceuticals, he co-founded Tellus Genetics, which was acquired by Maxygen in 2000. In addition, he has served as advisor to several corporate and governmental entities.
Dr. Shizuya received his M.D. and Ph.D. from Keio University School of Medicine in Japan and conducted postdoctoral work at Stanford University and Harvard University. Most recently, he was a member of professional staff, division of biology at California Institute of Technology.
Sean Stevens, Ph.D., Vice President, Research
Dr. Stevens serves as Ablexis’ vice president, research, leading the development of the AlivaMab Mouse platform. Dr. Stevens brings more than twenty years of experience in the fields of molecular immunology and B-cell biology, particularly as applied to the successful creation and utilization of transgenic mouse platforms for human therapeutic antibody drug discovery. He was a co-creator of the VelocImmune® Mouse at Regeneron, Inc., where he also identified therapeutic antibody drug targets, directed discovery and development programs for antibody drug candidates and built collaborative relationships with external corporate and academic partners. Most recently, he was with AnaptysBio, Inc., where he led a team involved in the development and application of an in vitro technology for creating human therapeutic antibodies. Dr. Stevens is an inventor on over 30 issued and pending patents on antibody discovery technologies, therapeutic product candidates and genetically-modified mouse models. Dr. Stevens holds a Ph.D. in molecular biology from the University of Pennsylvania and performed postdoctoral work at the Rockefeller University.